Gilead trumpets data with newly-bought magrolimab in blood c...

Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the lead drug from the deal, at ASCO 2020.

New combination trial firms up Venclexta’s prospects in AML

AbbVie/Roche's Venclexta fails in confirmatory AML trial

AbbVie and Roche's Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial that was supposed to confirm its efficacy.

BMS preps filings for leukaemia maintenance therapy CC-486

Astellas gets EU approval for AML drug Xospata

The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival dr

Astellas maintains lead over Daiichi Sankyo with CHMP okay f...